Results 121 to 130 of about 39,531 (226)

Severe Fever with Thrombocytopenia Syndrome Phlebovirus causes lethal viral hemorrhagic fever in cats. [PDF]

Sci Rep, 2019
Park ES, Shimojima M, Nagata N, Ami Y, Yoshikawa T, Iwata-Yoshikawa N, Fukushi S, Watanabe S, Kurosu T, Kataoka M, Okutani A, Kimura M, Imaoka K, Hanaki K, Suzuki T, Hasegawa H, Saijo M, Maeda K, Morikawa S.   +18 more
europepmc   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

Institutional readiness to provide critical care to patients with viral hemorrhagic fever (VHF) in the United States after the COVID-19 pandemic. [PDF]

Antimicrob Steward Healthc Epidemiol
DiLorenzo MA, LoPiccolo A, ElRayes W, Herstein JJ, Postelnicu R, Vasa A, Mukherjee V.   +6 more
europepmc   +1 more source

Exploring the Nutraceutical Potential of Achillea millefolium L.: Phytochemical Composition, Biological Activities, and Industrial Applications

Food Science &Nutrition, Volume 14, Issue 6, June 2026.
Achillea millefolium Linn., commonly known as yarrow, is an extraordinary medicinal plant. A. millefolium has broad therapeutic potential due to its phytochemistry and essential oil composition. It possesses pharmacological properties, including antidiabetic, antioxidant, anti‐inflammatory, liver‐protective, antimicrobial, and gastroprotective effects,
Tooba Majeed, Muhammad Tauseef Sultan, Ahmad Mujtaba Noman, Hassan Raza, Hagar M. Mohamed, Nimra Anees, Muhammad Imran, Muzzamal Hussain, Gamal A. Mohamed, Sabrin R. M. Ibrahim, Entessar Al Jbawi, Ehab M. Mostafa, Samy Selim, Ayman Salama, Mohamed A. Abdelgawad   +14 more
wiley   +1 more source

Development of a non-infectious control for viral hemorrhagic fever PCR assays. [PDF]

PLoS Negl Trop Dis
Knox MA, Bromhead C, Hayman DT.
europepmc   +1 more source

Exploring the Immunopathogenesis of Viral Hemorrhagic Fever in Mice with a Humanized Immune System. [PDF]

Front Immunol, 2017
Schönrich G, Raftery MJ.
europepmc   +1 more source

Understanding the delay in identifying Sudan Virus Disease: gaps in integrated disease surveillance and response and community-based surveillance to detect viral hemorrhagic fever outbreaks in Uganda, September 2022. [PDF]

BMC Infect Dis
Zalwango JF, Naiga HN, Nsubuga EJ, Akunzirwe R, Buhuguru R, Zalwango MG, Simbwa BN, Kizito SN, Kawungezi PC, Agaba B, Wanyana MW, Kabami Z, Ninsiima M, Zavuga R, King P, Kiggundu T, Nansikombi HT, Gonahasa DN, Kyamwine IB, Bulage L, Kwesiga B, Kadobera D, Migisha R, Ario AR, Harris JR.   +24 more
europepmc   +1 more source

Viral hemorrhagic fevers

, 2010
Lisa E. Hensley, Victoria Wahl-Jensen, Joseph B. McCormick, Kathleen H. Rubins   +3 more
openaire   +1 more source

[Evaluation of the Viral Hemorrhagic Fever Surveillance System in the Assaba region, Mauritania (2020-2022)]. [PDF]

Med Trop Sante Int
Boushab BM, Yanogo PK, Maham MH, Yoda H, Barry D, El-Bara A, Meda N.   +6 more
europepmc   +1 more source

Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First‐line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non‐comparative, Randomized Phase 2 Trial

MedComm, Volume 7, Issue 6, June 2026.
This phase II study explored the efficacy and safety of HAIC plus toripalimab in locally advanced HCC. The primary endpoint was the PFS rate at 6 months. The 6‐month PFS rate was 63.9% in the TorHAIC group and 61.1% in the SoraHAIC group. Treatment with the TorHAIC regimen resulted in a median OS of 20.9 months and a median PFS of 9.1 months.
Zhicheng Lai, Aojie Ge, Hanyue Ouyang, Zichao Wu, Yexing Huang, Qijiong Li, Li Xu, Binkui Li, Minshan Chen, Dongsheng Wen, Anna Kan, Ming Shi, Minke He   +12 more
wiley   +1 more source